Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefan Verweij

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Drug Discovery Today|December 3, 2024
Learning from European regulator-initiated studies for regulatory decision makingStefan Verweij, Just Weemers, Carla Jonker, et al.
Clinical Pharmacology and Therapeutics|February 12, 2024
A Natural Language Processing Approach Towards Harmonized Communication of Uncertainties Identified During the European Medicine Authorization ProcessStefan Verweij, Vincent Haverhoek, Erik Bergman, et al.
Health Promotion International|October 18, 2017
Implementing multiple intervention strategies in Dutch public health-related policy networksJanneke Harting, Dorothee Peters, Kimberly Grêaux, et al.
Applied Health Economics and Health Policy|November 16, 2023
Comment on: "The Assessment of Patient-Reported Outcomes for the Authorisation of Medicines in Europe: A Review of European Public Assessment Reports from 2017 to 2022"Sieta T de Vries, Noral Huda S Al-Mugoter, Irena Petkoska, et al.
Vaccine|August 1, 2023
Variability of in vivo potency assays of whole-cell pertussis, inactivated polio, and meningococcal B vaccinesCerissa van Walstijn, Stefan Verweij, Rory Care, et al.
European Journal of Epidemiology|March 18, 2026
A target trial emulation of the CONFIRM study with an extension to subgroups: an example for relapsing-remitting multiple sclerosisStefan Verweij, Maarten J Bijlsma, Katrien Oude Rengerink, et al.
Pharmacoepidemiology and Drug Safety|May 9, 2024
Do efficacy results obtained from randomized controlled trials translate to effectiveness data from observational studies for relapsing-remitting multiple sclerosis?Stefan Verweij, Wouter Ahmed, Guiling Zhou, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|February 19, 2025
Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection and severe outcomes in adults: a systematic review and meta-analysis of European studies published up to 22 January 2024Guiling Zhou, Nina Dael, Stefan Verweij, et al.
BMJ Open Respiratory Research|August 28, 2023
Repurposed drug studies on the primary prevention of SARS-CoV-2 infection during the pandemic: systematic review and meta-analysisGuiling Zhou, Stefan Verweij, Maarten J Bijlsma, et al.
Pharmaceuticals (Basel, Switzerland)|June 26, 2026
Repurposing Candidate Drugs to Prevent SARS-CoV-2: A PharmLines Test-Negative Case-Control StudyGuiling Zhou, Nina Dael, Stefan Verweij, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Drug Discovery Today|December 3, 2024
Learning from European regulator-initiated studies for regulatory decision makingStefan Verweij, Just Weemers, Carla Jonker, et al.
Clinical Pharmacology and Therapeutics|February 12, 2024
A Natural Language Processing Approach Towards Harmonized Communication of Uncertainties Identified During the European Medicine Authorization ProcessStefan Verweij, Vincent Haverhoek, Erik Bergman, et al.
Health Promotion International|October 18, 2017
Implementing multiple intervention strategies in Dutch public health-related policy networksJanneke Harting, Dorothee Peters, Kimberly Grêaux, et al.
Applied Health Economics and Health Policy|November 16, 2023
Comment on: "The Assessment of Patient-Reported Outcomes for the Authorisation of Medicines in Europe: A Review of European Public Assessment Reports from 2017 to 2022"Sieta T de Vries, Noral Huda S Al-Mugoter, Irena Petkoska, et al.
Vaccine|August 1, 2023
Variability of in vivo potency assays of whole-cell pertussis, inactivated polio, and meningococcal B vaccinesCerissa van Walstijn, Stefan Verweij, Rory Care, et al.
European Journal of Epidemiology|March 18, 2026
A target trial emulation of the CONFIRM study with an extension to subgroups: an example for relapsing-remitting multiple sclerosisStefan Verweij, Maarten J Bijlsma, Katrien Oude Rengerink, et al.
Pharmacoepidemiology and Drug Safety|May 9, 2024
Do efficacy results obtained from randomized controlled trials translate to effectiveness data from observational studies for relapsing-remitting multiple sclerosis?Stefan Verweij, Wouter Ahmed, Guiling Zhou, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|February 19, 2025
Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection and severe outcomes in adults: a systematic review and meta-analysis of European studies published up to 22 January 2024Guiling Zhou, Nina Dael, Stefan Verweij, et al.
BMJ Open Respiratory Research|August 28, 2023
Repurposed drug studies on the primary prevention of SARS-CoV-2 infection during the pandemic: systematic review and meta-analysisGuiling Zhou, Stefan Verweij, Maarten J Bijlsma, et al.
Pharmaceuticals (Basel, Switzerland)|June 26, 2026
Repurposing Candidate Drugs to Prevent SARS-CoV-2: A PharmLines Test-Negative Case-Control StudyGuiling Zhou, Nina Dael, Stefan Verweij, et al.
Pageof 2